Cargando…

The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir

BACKGROUND: Combination therapy with sofosbuvir (SOF) and simeprevir (SIM) is used to treat patients with hepatitis C virus infection. It is currently unknown whether adding ribavirin (RBV) to SOF + SIM, which raises the pill count from two up to eight pills a day, impacts adherence. The aim of this...

Descripción completa

Detalles Bibliográficos
Autores principales: Walker, David R, Juday, Timothy R, Manthena, Shivaji R, Jing, Yonghua, Sood, Vipan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687623/
https://www.ncbi.nlm.nih.gov/pubmed/26719716
http://dx.doi.org/10.2147/CEOR.S87261
_version_ 1782406648281694208
author Walker, David R
Juday, Timothy R
Manthena, Shivaji R
Jing, Yonghua
Sood, Vipan
author_facet Walker, David R
Juday, Timothy R
Manthena, Shivaji R
Jing, Yonghua
Sood, Vipan
author_sort Walker, David R
collection PubMed
description BACKGROUND: Combination therapy with sofosbuvir (SOF) and simeprevir (SIM) is used to treat patients with hepatitis C virus infection. It is currently unknown whether adding ribavirin (RBV) to SOF + SIM, which raises the pill count from two up to eight pills a day, impacts adherence. The aim of this study is to examine the impact of pill count on real-world adherence rates in patients treated with SOF + SIM with and without RBV. METHODS: This retrospective study assessed composite adherence to SOF and SIM over 12 weeks of treatment for two cohorts of hepatitis C patients: one initiating SOF + SIM therapy, and the other initiating SOF + SIM + RBV therapy. Analyses were conducted using MarketScan(®) and Optum US commercial pharmacy claims and enrollment data. Adherence was adjusted by treatment regimen, age, sex, co-pay, presence/absence of cirrhosis, treatment history, and Charlson Comorbidity Index. RESULTS: There was a significant difference in composite unadjusted and adjusted adherence rates for SOF and SIM for the SOF + SIM vs SOF + SIM + RBV cohorts based on MarketScan data (unadjusted, 92.6% and 89.7%, respectively; P=0.0423; adjusted, 92.2% and 88.7%, respectively; P=0.0176), but not based on Optum data (unadjusted, 94.8% and 95.6%, respectively; P=0.5618; adjusted, 94.8% and 95.1%, respectively; P=0.8589). In the MarketScan and Optum databases, there were no statistical differences in unadjusted and adjusted adherence rates for SOF. Unadjusted and adjusted adherence rates for SIM were mixed, as they were for composite adherence. CONCLUSION: The impact of the addition of RBV to SOF + SIM therapy was mixed. The impact of RBV on SOF adherence was not significant in either database.
format Online
Article
Text
id pubmed-4687623
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-46876232015-12-30 The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir Walker, David R Juday, Timothy R Manthena, Shivaji R Jing, Yonghua Sood, Vipan Clinicoecon Outcomes Res Original Research BACKGROUND: Combination therapy with sofosbuvir (SOF) and simeprevir (SIM) is used to treat patients with hepatitis C virus infection. It is currently unknown whether adding ribavirin (RBV) to SOF + SIM, which raises the pill count from two up to eight pills a day, impacts adherence. The aim of this study is to examine the impact of pill count on real-world adherence rates in patients treated with SOF + SIM with and without RBV. METHODS: This retrospective study assessed composite adherence to SOF and SIM over 12 weeks of treatment for two cohorts of hepatitis C patients: one initiating SOF + SIM therapy, and the other initiating SOF + SIM + RBV therapy. Analyses were conducted using MarketScan(®) and Optum US commercial pharmacy claims and enrollment data. Adherence was adjusted by treatment regimen, age, sex, co-pay, presence/absence of cirrhosis, treatment history, and Charlson Comorbidity Index. RESULTS: There was a significant difference in composite unadjusted and adjusted adherence rates for SOF and SIM for the SOF + SIM vs SOF + SIM + RBV cohorts based on MarketScan data (unadjusted, 92.6% and 89.7%, respectively; P=0.0423; adjusted, 92.2% and 88.7%, respectively; P=0.0176), but not based on Optum data (unadjusted, 94.8% and 95.6%, respectively; P=0.5618; adjusted, 94.8% and 95.1%, respectively; P=0.8589). In the MarketScan and Optum databases, there were no statistical differences in unadjusted and adjusted adherence rates for SOF. Unadjusted and adjusted adherence rates for SIM were mixed, as they were for composite adherence. CONCLUSION: The impact of the addition of RBV to SOF + SIM therapy was mixed. The impact of RBV on SOF adherence was not significant in either database. Dove Medical Press 2015-12-17 /pmc/articles/PMC4687623/ /pubmed/26719716 http://dx.doi.org/10.2147/CEOR.S87261 Text en © 2015 Walker et al. This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution – Non Commercial (unported, v3.0) License The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Walker, David R
Juday, Timothy R
Manthena, Shivaji R
Jing, Yonghua
Sood, Vipan
The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir
title The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir
title_full The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir
title_fullStr The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir
title_full_unstemmed The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir
title_short The impact of ribavirin on real-world adherence rates in hepatitis C patients treated with sofosbuvir plus simeprevir
title_sort impact of ribavirin on real-world adherence rates in hepatitis c patients treated with sofosbuvir plus simeprevir
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4687623/
https://www.ncbi.nlm.nih.gov/pubmed/26719716
http://dx.doi.org/10.2147/CEOR.S87261
work_keys_str_mv AT walkerdavidr theimpactofribavirinonrealworldadherenceratesinhepatitiscpatientstreatedwithsofosbuvirplussimeprevir
AT judaytimothyr theimpactofribavirinonrealworldadherenceratesinhepatitiscpatientstreatedwithsofosbuvirplussimeprevir
AT manthenashivajir theimpactofribavirinonrealworldadherenceratesinhepatitiscpatientstreatedwithsofosbuvirplussimeprevir
AT jingyonghua theimpactofribavirinonrealworldadherenceratesinhepatitiscpatientstreatedwithsofosbuvirplussimeprevir
AT soodvipan theimpactofribavirinonrealworldadherenceratesinhepatitiscpatientstreatedwithsofosbuvirplussimeprevir
AT walkerdavidr impactofribavirinonrealworldadherenceratesinhepatitiscpatientstreatedwithsofosbuvirplussimeprevir
AT judaytimothyr impactofribavirinonrealworldadherenceratesinhepatitiscpatientstreatedwithsofosbuvirplussimeprevir
AT manthenashivajir impactofribavirinonrealworldadherenceratesinhepatitiscpatientstreatedwithsofosbuvirplussimeprevir
AT jingyonghua impactofribavirinonrealworldadherenceratesinhepatitiscpatientstreatedwithsofosbuvirplussimeprevir
AT soodvipan impactofribavirinonrealworldadherenceratesinhepatitiscpatientstreatedwithsofosbuvirplussimeprevir